Inhibitory effects of anticardiolipin antibodies on lymphocyte proliferation and neutrophil phagocytosis.
Open Access
- 1 December 1991
- journal article
- research article
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 50 (12) , 903-908
- https://doi.org/10.1136/ard.50.12.903
Abstract
Anticardiolipin antibodies purified from serum from patients with systemic lupus erythematosus (SLE) by cardiolipin micelles were studied for their effects on lymphocytes and neutrophils. At a concentration of 160 micrograms/ml they markedly suppressed the [3H]thymidine incorporation of mononuclear cells stimulated by phytohaemagglutinin (4.9 (SEM 1.9%) of the control) and pokeweed mitogen (26.7 (10.5%) of the control). In addition, anticardiolipin antibodies changed the cell cycle of phytohaemagglutinin stimulated lymphocytes such that the S and G2+M phases were significantly diminished (G0/G1 = 64.62%, S = 20.59%, G2+M = 14.78% in the presence of normal human IgG v G0/G1 = 86.07%, S = 10.32%, G2+M = 3.59% in the presence of anticardiolipin antibodies). The suppression of lymphocyte proliferation by anticardiolipin antibodies was shown not to be caused by an alteration of T cell subpopulations. However, the interleukin 2 receptors on the cell surface and the soluble interleukin 2 receptors in the supernatant of phytohaemagglutinin stimulated mononuclear cells were decreased in the presence of anticardiolipin antibodies. On the other hand, the phagocytic activity of neutrophils was 40% inhibited at a higher concentration of anticardiolipin antibodies (300 micrograms/ml) through suppression of C3b/C4b and Fc receptors on polymorphonuclear leucocytes. These results suggest that anticardiolipin antibodies exert inhibitory effects on both lymphocytes and phagocytes in addition to the coagulation cascade. These newly found activities of anticardiolipin antibodies were mediated by the non-specific membranotropic property of the antibodies.Keywords
This publication has 39 references indexed in Scilit:
- The tumor necrosis factor receptor and human neutrophil function. Deactivation and cross-deactivation of tumor necrosis factor-induced neutrophil responses by receptor down-regulation.Journal of Clinical Investigation, 1990
- Interleukin 1 and tumor necrosis factor stimulate human vascular endothelial cells to promote transendothelial neutrophil passage.Journal of Clinical Investigation, 1989
- Anticardiolipin response in acute infectionsClinical Immunology and Immunopathology, 1986
- Lupus anticoagulant: An analysis of the clinical and laboratory features of 219 casesAmerican Journal of Hematology, 1985
- LUPUS ANTICOAGULANT, RECURRENT ABORTION, AND PROSTACYCLIN PRODUCTION BY CULTURED SMOOTH MUSCLE CELLSThe Lancet, 1983
- The 1982 revised criteria for the classification of systemic lupus erythematosusArthritis & Rheumatism, 1982
- Incidence of infection in systemic lupus erythematosusArthritis & Rheumatism, 1974
- The asymmetric arrangement of phospholipids in the human erythrocyte membraneBiochemical and Biophysical Research Communications, 1973
- Impaired delayed hypersensitivity in systemic lupus erythematosusArthritis & Rheumatism, 1972
- REGULATION OF THE IMMUNE RESPONSEThe Journal of Experimental Medicine, 1969